IN2014KN02935A - - Google Patents
Info
- Publication number
- IN2014KN02935A IN2014KN02935A IN2935KON2014A IN2014KN02935A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A IN 2935KON2014 A IN2935KON2014 A IN 2935KON2014A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A
- Authority
- IN
- India
- Prior art keywords
- 6alkyl
- hydrogen
- 6alkoxy
- proviso
- hydroxy
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150094373 Padi4 gene Proteins 0.000 abstract 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/064649 WO2014015905A1 (fr) | 2012-07-26 | 2012-07-26 | 2-(azaindol-2-yl)benzimidazoles utilisés comme inhibiteurs de pad4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02935A true IN2014KN02935A (fr) | 2015-05-08 |
Family
ID=49996626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2935KON2014 IN2014KN02935A (fr) | 2012-07-26 | 2012-07-26 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9127003B2 (fr) |
| EP (1) | EP2877467B1 (fr) |
| JP (1) | JP6063567B2 (fr) |
| KR (1) | KR101916443B1 (fr) |
| CN (1) | CN104470919B (fr) |
| AU (1) | AU2012386257B2 (fr) |
| BR (1) | BR112015001545B1 (fr) |
| CA (1) | CA2879341C (fr) |
| CY (1) | CY1118524T1 (fr) |
| DK (1) | DK2877467T3 (fr) |
| ES (1) | ES2609126T3 (fr) |
| HR (1) | HRP20161530T1 (fr) |
| HU (1) | HUE033294T2 (fr) |
| IN (1) | IN2014KN02935A (fr) |
| LT (1) | LT2877467T (fr) |
| PL (1) | PL2877467T3 (fr) |
| PT (1) | PT2877467T (fr) |
| RS (1) | RS55684B1 (fr) |
| RU (1) | RU2611010C2 (fr) |
| SI (1) | SI2877467T1 (fr) |
| SM (2) | SMT201700052T1 (fr) |
| WO (1) | WO2014015905A1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016185279A1 (fr) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de benzoimidazole en tant qu'inhibiteurs de pad4 |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| SG11201807021UA (en) * | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| CN107188867A (zh) * | 2016-03-14 | 2017-09-22 | 中国科学院天津工业生物技术研究所 | 精氨酸脱亚氨酶4的抑制剂 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
| KR102502992B1 (ko) * | 2016-09-12 | 2023-02-24 | 패들락 테라퓨틱스, 인코포레이티드 | Pad4의 헤테로아릴 억제제 |
| WO2018102262A1 (fr) * | 2016-12-02 | 2018-06-07 | University Of Massachusetts | Inhibiteurs de protéine arginine déiminases (pad) et procédés de préparation et d'utilisation associés |
| CN108689946B (zh) * | 2017-04-12 | 2022-10-18 | 中国科学院上海药物研究所 | 2-取代硫基乙酰胺类化合物及其制备方法和应用 |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| CN110194770B (zh) * | 2018-02-26 | 2022-08-09 | 药捷安康(南京)科技股份有限公司 | 肽酰精氨酸脱亚胺酶抑制剂及其用途 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| MX2021001471A (es) * | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| ES2929200T3 (es) | 2018-08-08 | 2022-11-25 | Bristol Myers Squibb Co | Tienopirroles sustituidos como inhibidores de PAD4 |
| EP3833440A1 (fr) | 2018-08-08 | 2021-06-16 | Bristol-Myers Squibb Company | Inhibiteurs indoles et azaindoles d'enzymes pad |
| ES2956090T3 (es) | 2018-08-08 | 2023-12-13 | Bristol Myers Squibb Co | Inhibidores de bencimidazol de enzimas PAD |
| CN109369513B (zh) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | 一种fbdd常用分子片段的制备方法 |
| CA3123215C (fr) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs |
| EP3994128A4 (fr) * | 2019-07-03 | 2022-12-07 | University of Massachusetts | Inhibiteurs de la protéine arginine déiminase (pad) et leurs méthodes de préparation et d'utilisation |
| TW202115083A (zh) * | 2019-09-27 | 2021-04-16 | 大陸商南京藥捷安康生物科技有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| CN115298175B (zh) * | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| TW202140477A (zh) * | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| CN111265526B (zh) * | 2020-04-09 | 2021-03-19 | 黑龙江中医药大学 | 一种治疗胃癌的药物及其制备方法 |
| MX2022013615A (es) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Inhibidores de macrociclo de peptidilarginina deiminasas. |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| EP4215534B1 (fr) | 2020-09-18 | 2026-06-24 | Carna Biosciences, Inc. | Dérivé d'amine |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| EP4267562A1 (fr) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibiteurs de peptidylarginine déiminases |
| JP2024543517A (ja) | 2021-11-15 | 2024-11-21 | レゴー・ファーマシューティカルズ，インコーポレーテッド | Ｐａｄ４阻害剤及びその使用 |
| WO2023203135A1 (fr) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Anticorps radiomarqué amélioré |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| EP4531849A4 (fr) * | 2022-05-26 | 2026-05-20 | Celgene Corp | Inhibiteurs de pad4 hétérocycliques |
| KR20250027600A (ko) * | 2022-05-26 | 2025-02-26 | 셀진 코포레이션 | 헤테로시클릭 pad4 억제제 |
| AU2023387505B2 (en) * | 2022-11-24 | 2026-03-05 | Helios Huaming Biopharma Co., Ltd. | Selenium containing heterocycle compounds and use thereof |
| WO2025024265A1 (fr) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Procédés d'évaluation de la citrullination et de l'activité de modulateurs de pad4 |
| WO2026020127A2 (fr) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Procédés d'évaluation de la citrullination et de l'activité des modulateurs de pad2 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| DE69622166T2 (de) | 1995-04-14 | 2003-04-03 | Smithkline Beecham Corp., Philadelphia | Dosierinhalator für albuterol |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| CZ2001959A3 (cs) * | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| AU778042B2 (en) * | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| HUP0203895A3 (en) | 1999-12-24 | 2004-09-28 | Aventis Pharma Ltd West Mallin | Substituted azaindoles and pharmaceutical compositions containing them and their use |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (fr) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthese de composes heterocycliques faisant appel a une technologie micro-onde |
| BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
| MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| US7429611B2 (en) * | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
| EP2205085A1 (fr) | 2007-09-25 | 2010-07-14 | Merck Sharp & Dohme Corp. | Dérivés d'indole 2-aryle ou hétéroaryle |
| EP2300460A1 (fr) | 2008-05-28 | 2011-03-30 | Wyeth LLC | Composés de 1h-indole 3 substitués, leur utilisation en tant qu'inhibiteurs de 3mtor kinase et p13 kinase, et leurs synthèses |
| RU2011106786A (ru) * | 2008-07-23 | 2012-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы пиразолопиридинкиназы |
| SG174125A1 (en) | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| WO2010118208A1 (fr) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Dérivés benzoxazepin-4-(5h)-yle et leur utilisation pour traiter le cancer |
-
2012
- 2012-07-26 RU RU2014152456A patent/RU2611010C2/ru active
- 2012-07-26 IN IN2935KON2014 patent/IN2014KN02935A/en unknown
- 2012-07-26 LT LTEP12740581.9T patent/LT2877467T/lt unknown
- 2012-07-26 WO PCT/EP2012/064649 patent/WO2014015905A1/fr not_active Ceased
- 2012-07-26 KR KR1020157005099A patent/KR101916443B1/ko active Active
- 2012-07-26 PT PT127405819T patent/PT2877467T/pt unknown
- 2012-07-26 RS RS20170121A patent/RS55684B1/sr unknown
- 2012-07-26 US US14/416,937 patent/US9127003B2/en active Active
- 2012-07-26 EP EP12740581.9A patent/EP2877467B1/fr active Active
- 2012-07-26 AU AU2012386257A patent/AU2012386257B2/en active Active
- 2012-07-26 JP JP2015523426A patent/JP6063567B2/ja active Active
- 2012-07-26 SM SM20170052T patent/SMT201700052T1/it unknown
- 2012-07-26 PL PL12740581T patent/PL2877467T3/pl unknown
- 2012-07-26 SI SI201230769A patent/SI2877467T1/sl unknown
- 2012-07-26 HU HUE12740581A patent/HUE033294T2/en unknown
- 2012-07-26 CA CA2879341A patent/CA2879341C/fr active Active
- 2012-07-26 CN CN201280074868.5A patent/CN104470919B/zh active Active
- 2012-07-26 HR HRP20161530TT patent/HRP20161530T1/hr unknown
- 2012-07-26 ES ES12740581.9T patent/ES2609126T3/es active Active
- 2012-07-26 BR BR112015001545-0A patent/BR112015001545B1/pt active IP Right Grant
- 2012-07-26 DK DK12740581.9T patent/DK2877467T3/en active
-
2015
- 2015-08-03 US US14/816,246 patent/US9518054B2/en active Active
-
2016
- 2016-11-15 US US15/352,340 patent/US9833449B2/en active Active
-
2017
- 2017-01-24 SM SM201700052T patent/SMT201700052B/it unknown
- 2017-01-27 CY CY20171100128T patent/CY1118524T1/el unknown
- 2017-11-20 US US15/817,562 patent/US10039755B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118524T1 (el) | 2-(αζαϊνδολ-2-υλο)βενζιμιδαζολια ως pad4 αναστολεις | |
| MX387321B (es) | Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2020003242A (es) | Compuestos heterociclicos como inhibidores de pad. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2020003341A (es) | Compuestos de imidazo-piridina como inhibidores de pad. | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| CY1118656T1 (el) | Παραγωγο πυριδονης | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| MX2015000129A (es) | Derivados de pirimidin pirazolilo. | |
| MX351471B (es) | Derivados de piridinona y pirimidinona como inhibidores del factor xia. | |
| MX389105B (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret). | |
| TN2015000245A1 (en) | Heterocyclic compound | |
| NZ702070A (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| PH12014502788B1 (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | |
| IL244392A0 (en) | Use of a preparation containing microorganisms to increase intestinal production of butyric acid, folic acid or niacin and/or reduce intestinal production of succinic acid | |
| MX2019000686A (es) | Sales de acido diorganilfosfinico, metodo para su produccion y su uso. | |
| MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
| WO2014144374A3 (fr) | Procédé pour la production de carbone pur, compositions et procédés pour ceci | |
| MY178390A (en) | Inhibitors of iap | |
| MX2017010624A (es) | Derivado de amina ciclica y su uso farmaceutico. | |
| MX2017005423A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
| MX2017007577A (es) | Compuestos de dihidropirimidin-2-ona y su uso medico. | |
| MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
| MX2021015514A (es) | Compuesto heterociclico. | |
| MX369345B (es) | Procesos para la preparacion de analogos de oxitocina. |